Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?

Simple item page
dc.contributor.authorvan Til, Janine A.
dc.contributor.authorKip, Michelle M. A.
dc.contributor.authorSchatorjé, Ellen J. H.
dc.contributor.authorCurrie, Gillian
dc.contributor.authorTwilt, Marinka
dc.contributor.authorBenseler, Susanne M.
dc.contributor.authorSwart, Joost F.
dc.contributor.authorVastert, Sebastiaan J.
dc.contributor.authorWulffraat, Nico
dc.contributor.authorYeung, Rae S. M.
dc.contributor.authorGroothuis-Oudshoorn, C. G. M. (.
dc.contributor.authorWarta, Sanne
dc.contributor.authorMarshall, Deborah A.
dc.contributor.authorIJzerman, Maarten J.
dc.date.accessioned2023-07-16T00:03:00Z
dc.date.available2023-07-16T00:03:00Z
dc.date.issued2023-07-11
dc.date.updated2023-07-16T00:03:00Z
dc.description.abstractAbstract Objective Approximately one third of children with JIA receive biologic therapy, but evidence on biologic therapy withdrawal is lacking. This study aims to increase our understanding of whether and when pediatric rheumatologists postpone a decision to withdraw biologic therapy in children with clinically inactive non-systemic JIA. Methods A survey containing questions about background characteristics, treatment patterns, minimum treatment time with biologic therapy, and 16 different patient vignettes, was distributed among 83 pediatric rheumatologists in Canada and the Netherlands. For each vignette, respondents were asked whether they would withdraw biologic therapy at their minimum treatment time, and if not, how long they would continue biologic therapy. Statistical analysis included descriptive statistics, logistic and interval regression analysis. Results Thirty-three pediatric rheumatologists completed the survey (40% response rate). Pediatric rheumatologists are most likely to postpone the decision to withdraw biologic therapy when the child and/or parents express a preference for continuation (OR 6.3; p < 0.001), in case of a flare in the current treatment period (OR 3.9; p = 0.001), and in case of uveitis in the current treatment period (OR 3.9; p < 0.001). On average, biologic therapy withdrawal is initiated 6.7 months later when the child or parent prefer to continue treatment. Conclusion Patient’s and parents' preferences were the strongest driver of a decision to postpone biologic therapy withdrawal in children with clinically inactive non-systemic JIA and prolongs treatment duration. These findings highlight the potential benefit of a tool to support pediatric rheumatologists, patients and parents in decision making, and can help inform its design.
dc.identifier.citationPediatric Rheumatology. 2023 Jul 11;21(1):69
dc.identifier.urihttps://doi.org/10.1186/s12969-023-00845-4
dc.identifier.urihttps://hdl.handle.net/1880/116731
dc.identifier.urihttps://dx.doi.org/10.11575/PRISM/41573
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titleWithdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12969_2023_Article_845.pdf
Size:
964.26 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.25 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications